Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 3 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 39 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
OncoRNA from Charleroi, company number BE0805162158, closed financial year 2025 with a result of € -15,560 after tax. For that financial year OncoRNA recorded a gross margin of € -15,237 and equity of € -31,846. Compared with financial year 2024, the result moved from € -38,269 to € -15,560. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.
€ -31,846
▼ € 15,560 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -15,560
▲ 59 % less loss than in 2024
Profit after tax over the fiscal year.
€ 19,424
▲ 29% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -93,346.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € -37,946 | € -36,306 | € -15,237 | ▲ € 21,069 |
| Profit after taxes | € -39,517 | € -38,269 | € -15,560 | ▲ € 22,708 |
| Equity | € 21,983 | € -16,286 | € -31,846 | ▼ € 15,560 |
| Total debts | € 5,854 | € 32,882 | € 51,880 | ▲ 58% |
| Cash | € 23,947 | € 15,028 | € 19,424 | ▲ 29% |
| Retained profit | € -39,517 | € -77,786 | € -93,346 | ▼ € 15,560 |
| Balance sheet total | € 27,837 | € 16,596 | € 20,034 | ▲ 21% |
Key figures of OncoRNA, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OncoRNA?
What happened at OncoRNA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- ONCODNA SA stepped down as director. NBB
- François BLONDEL stepped down as director. NBB
- Christophe VAN HUFFEL stepped down as director. NBB
- Jean-Pol DETIFFE stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 15,560. Source: NBB ↗
- New establishment in Charleroi. KBO
- ONCODNA SA became a director. NBB
- François BLONDEL became a director. NBB
In short
From € 39,517 loss in 2023 to € 15,560 loss in 2025.
Management
Directors
According to the 2025 annual accounts
Director · represented by Charles-André BROUWERS
since 2023 · until 2029
François BLONDEL
Director
since 2023 · until 2029
since 2023 · until 2029
Jean-Pol DETIFFE
Director
Also active at: Société de Développement et de Participation du Bassin de Charleroi, SAMBRELEASE, FONDS DE CAPITAL A RISQUE 2020, 6K venture capital, SAMBRINVEST SPIN-OFF/SPIN-OUT
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Rue Louis Breguet 1
6041 Charleroi
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0805.162.158
- VAT number
- BE 0805.162.158
- Registered office
- Rue Louis Breguet 1, 6041 Charleroi
- Names & denominations
- OncoRNA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 August 2023
- Peppol
- Active · Active since 25 Nov 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van overige farmaceutische producten
Vervaardiging van geneesmiddelen